October 22, 2013 - ReproTech, Ltd. was proud to sponsor local staff in Susan G. Komen for the Cure fundraisers.
ReproTech, Ltd. sponsored its Reno, NV and Mesquite, TX staff and their teams in the Northern Nevada and Dallas Race for the Cure teams this October, Breast Cancer Awareness Month. Congratulations to the more than 4,000 Northern Nevada participants whose teams raised over $200,000, and to the over 20,000 Dallas participants who braved the cold morning to raise over $1.4 million.
Other October events raising money for breast cancer included the "Strike Out Cancer" soft ball tournament in which the daughter of ReproTech's Reno site director participated with her team the Lady Aces. The Lady Aces also wrapped up their own fund raiser "Crush it for Cancer", bringing in over $300 for the Northern Nevada Children's Cancer Foundation.
ReproTech regularly sponsors or contributes funds to cancer fundraising events in the areas where its employees and four regional facilities reside, Ft. Lauderdale/Coconut Creek, Florida; Minneapolis/St. Paul, Minnesota, Reno, Nevada; and Dallas/Mesquite, Texas.
For the 140,000 American men and women under age 45 who are newly diagnosed with cancer each year, chemotherapy and other treatments can affect their reproductive system and fertility. There is often a small window of time for these men and women to preserve their fertility; therefore, access to cryopreservation services is extremely important. Both the American Society of Clinical Oncology (ASCO) and American Society for Reproductive Medicine (ASRM) recommend the education of oncology patients about the options available to preserve their fertility.
ReproTech, Ltd. has organized the Fertility Preservation Network to educate oncology professionals and caretakers, as well as provide much needed cryopreservation services for men and women. The network now includes members in 35 states and the Caribbean. Additionally, the work of fertileHOPE and LiveSTRONG has advanced the awareness of the need for Fertility Preservation among the oncology community.